Sun Pharma to market its own version of Vortioxetine, signs agreement with Lundbeck

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder in adults.

Published On 2022-03-31 06:32 GMT   |   Update On 2022-03-31 06:32 GMT
Advertisement

Mumbai: Sun Pharmaceutical Industries Limited today announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIF. The territory of the licensing agreement will only cover India.

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada, and Australia.

Advertisement

Read Also - Sun Pharma gets CDSCO nod to market Tofacitinib to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, "Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavor to bring innovative medicines that fill a need gap. MDD is a serious and complicated disorder and Vortidif will serve as an important novel treatment option for patients in India."

MDD is one of the leading causes of disability, affecting approximately 246 million people globally and 35 million people in India. MDD is characterized by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behavior.

Read Also - Sun Pharma arm presents phase 3 data for acne vulgaris cream WINLEVI at AAD meeting

Sun Pharma is ranked No. 1 by prescriptions and value amongst Neurologists & Psychiatrists in India. With a strong product portfolio, Sun Pharma's CNS division constantly strives to provide innovative solutions to patients and health care providers in India.

H. Lundbeck is a global pharmaceutical company specializing in brain diseases.

Read Also - Sun Pharma gets CDSCO panel nod to conduct phase 4 study of Cyclosporine Ophthalmic Solution






Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News